Describing the state of mentoring in academic dermatology.

already ill infant). As a retrospective study this report has all the weaknesses inherent in that design. Since only those infants admitted were reviewed, those infants who had complications as outpatients would be missed. It is not clear whether patients with HOI would be expected to exhibit a similar or lesser risk of complications when compared with those infants treated for cardiac issues. Accumulating data suggest that bronchospasm and/or respiratory issues are frequent complications that can occur at any point during propranolol treatment. Many studies suggest that most complications from propranolol therapy do not occur during the initial drug dosing initiation period. Dermatologists who treat infants with propranolol should ask parents about respiratory symptoms such as wheezing, cough, or stridor at each follow-up visit while the infant is taking propranolol. There is great debate regarding appropriate monitoring protocols for initiating and maintaining propranolol therapy in infants with HOI. What are the right parameters to follow? Should it be as an inpatient or an outpatient? Future studies will address these questions. At present though, reports such as this highlight the relative safety of using propranolol in young children and suggest that propranolol treatment may be safely initiated in an outpatient setting in healthy infants.